Literature DB >> 28001297

Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.

M Amato1, H Schennach1, M Astl1, C Y Chen2, J-S Lin2, R J Benjamin2, W Nussbaumer1.   

Abstract

BACKGROUND: In clinical studies, pathogen inactivation (PI) of platelet concentrates (PC) with amotosalen and UVA light did not impact patient risk for haemorrhage but may affect transfusion frequency and component utilization. We evaluated the influence of platelet PI on PC, red cell concentrate (RCC) and plasma use and safety in routine practice in a large regional hospital. STUDY DESIGN AND METHODS: Comparative effectiveness of conventional vs. PI-treated PC was analysed during two 21-month periods, before and after PI implementation.
RESULTS: Similar numbers of patients were transfused in the pre-PI (control, 1797) and post-PI (test, 1694) periods with comparable numbers of PC (8611 and 7705, respectively). The mean numbers of PC per patient transfused (4·8 vs. 4·5, P = 0·43) were not different but days of PC support (5·9 vs. 5·0, P < 0·01) decreased. Most patients received RCC (86·8% control vs. 84·8% test, P = 0·90) with similar mean numbers transfused (10·8 vs. 10·2 RCC, P = 0·22), and fewer patients (55·4% control vs. 44·7% test, P < 0·01) received less plasma units (mean 9·9 vs. 7·8, respectively, P < 0·01) in the test period. The frequencies of transfusion-related adverse events (AE) were comparable (1·3% vs. 1·4%, P = 0·95). Analysis of haematology-oncology (522 control, 452 test), cardiac surgery (739 control, 711 test), paediatric (157 control, 130 test) and neonate (23 control, 20 test) patients revealed no increase in PC, plasma and RCC utilization, or AE.
CONCLUSION: Component utilization and patient safety were not impacted by adoption of PI for PC. RCC use per patient was comparable, suggestive of no increase in significant bleeding.
© 2016 The Authors. Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion.

Entities:  

Keywords:  INTERCEPT Blood System; amotosalen; haemovigilance; pathogen inactivation; platelets; safety

Mesh:

Substances:

Year:  2016        PMID: 28001297     DOI: 10.1111/vox.12456

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  15 in total

1.  Amotosalen/UVA pathogen inactivation technology reduces platelet activability, induces apoptosis and accelerates clearance.

Authors:  Beatrice Hechler; Catherine Ravanat; Christian Gachet
Journal:  Haematologica       Date:  2017-12       Impact factor: 9.941

2.  What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

3.  Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system.

Authors:  Americo Cicchetti; Silvia Coretti; Francesco Sacco; Paolo Rebulla; Alessandra Fiore; Filippo Rumi; Rossella Di Bidino; Luz I Urbina; Pietro Refolo; Dario Sacchini; Antonio G Spagnolo; Emanuela Midolo; Giuseppe Marano; Blandina Farina; Ilaria Pati; Eva Veropalumbo; Simonetta Pupella; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443

4.  The argument(s) for lowering the US minimum required content of apheresis platelet components.

Authors:  Richard J Benjamin; Louis Katz; Richard R Gammon; Susan L Stramer; Eva Quinley
Journal:  Transfusion       Date:  2018-11-21       Impact factor: 3.157

5.  Economic Implications of Pathogen Reduced and Bacterially Tested Platelet Components: A US Hospital Budget Impact Model.

Authors:  Katherine M Prioli; Julie Katz Karp; Nina M Lyons; Vera Chrebtow; Jay H Herman; Laura T Pizzi
Journal:  Appl Health Econ Health Policy       Date:  2018-12       Impact factor: 2.561

6.  Evaluation of bacterial inactivation in random donor platelets and single-donor apheresis platelets by the INTERCEPT blood system.

Authors:  Raj Nath Makroo; Raman Sardana; Leena Mediratta; Hena Butta; Uday Kumar Thakur; Soma Agrawal; Mohit Chowdhry; Satendra Kumar; Sourit Chokroborty
Journal:  Asian J Transfus Sci       Date:  2018 Jul-Dec

7.  Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026).

Authors:  Chintamani Atreya; Simone Glynn; Michael Busch; Steve Kleinman; Edward Snyder; Sara Rutter; James AuBuchon; Willy Flegel; David Reeve; Dana Devine; Claudia Cohn; Brian Custer; Raymond Goodrich; Richard J Benjamin; Anna Razatos; Jose Cancelas; Stephen Wagner; Michelle Maclean; Monique Gelderman; Andrew Cap; Paul Ness
Journal:  Transfusion       Date:  2019-05-29       Impact factor: 3.157

8.  How do we … integrate pathogen reduced platelets into our hospital blood bank inventory?

Authors:  Sara Rutter; Edward L Snyder
Journal:  Transfusion       Date:  2019-03-18       Impact factor: 3.157

9.  Transfusion of pathogen-reduced platelet components without leukoreduction.

Authors:  Joycelyn Sim; Wai Chiu Tsoi; Cheuk Kwong Lee; Rock Leung; Clarence C K Lam; Claudia Koontz; Amy Yingjie Liu; Norman Huang; Richard J Benjamin; Hans J Vermeij; Adonis Stassinopoulos; Laurence Corash; Albert K W Lie
Journal:  Transfusion       Date:  2019-03-28       Impact factor: 3.157

Review 10.  Bacterial contamination of platelets for transfusion: strategies for prevention.

Authors:  Jerrold H Levy; Matthew D Neal; Jay H Herman
Journal:  Crit Care       Date:  2018-10-27       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.